Ionis Pharmaceuticals: Digesting Recent Events
Source: SeekingAlpha
2026-02-27 02:54:16 ET
Shares of antisense therapy concern Ionis Pharmaceuticals, Inc. ( IONS ) have rallied strongly since its familial chylomicronemia syndrome med Tryngolza (olezarsen) bore strong data treating severe hypertriglyceridemia. Announced in September 2025, the results suggest it will be the new standard of care for the indication, prompting management to raise its peak revenue estimate by $1 billion to >$2 billion. The stock fell five percent in trading Wednesday after the company posted Q4 numbers. Management repeated its guidance for peak sales for Tryngolza following fourth quarter results....
Read the full article on Seeking Alpha
For further details see:
Ionis Pharmaceuticals: Digesting Recent Events
Intellia Therapeutics Inc.
NASDAQ: NTLA
NTLA Trading
-1.05% G/L:
$13.8339 Last:
1,221,299 Volume:
$13.64 Open:
NTLA Latest News
March 03, 2026 07:30:00 am
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
March 02, 2026 07:30:00 am
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
NTLA Stock Data
$1,420,074,893
112,239,198
1.45%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
